Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients.
Details
Serval ID
serval:BIB_36E7457158FD
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients.
Journal
The Journal of experimental medicine
ISSN
1540-9538 (Electronic)
ISSN-L
0022-1007
Publication state
Published
Issued date
04/09/2023
Peer-reviewed
Oui
Volume
220
Number
9
Pages
e20230661
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Mosquito-borne West Nile virus (WNV) infection is benign in most individuals but can cause encephalitis in <1% of infected individuals. We show that ∼35% of patients hospitalized for WNV disease (WNVD) in six independent cohorts from the EU and USA carry auto-Abs neutralizing IFN-α and/or -ω. The prevalence of these antibodies is highest in patients with encephalitis (∼40%), and that in individuals with silent WNV infection is as low as that in the general population. The odds ratios for WNVD in individuals with these auto-Abs relative to those without them in the general population range from 19.0 (95% CI 15.0-24.0, P value <10-15) for auto-Abs neutralizing only 100 pg/ml IFN-α and/or IFN-ω to 127.4 (CI 87.1-186.4, P value <10-15) for auto-Abs neutralizing both IFN-α and IFN-ω at a concentration of 10 ng/ml. These antibodies block the protective effect of IFN-α in Vero cells infected with WNV in vitro. Auto-Abs neutralizing IFN-α and/or IFN-ω underlie ∼40% of cases of WNV encephalitis.
Keywords
Animals, Chlorocebus aethiops, Humans, West Nile Fever, West Nile virus, Vero Cells, Autoantibodies, Antibodies, Viral, Interferon Type I, Interferon-alpha
Pubmed
Web of science
Open Access
Yes
Create date
26/06/2023 11:11
Last modification date
08/08/2024 6:31